Discovery of a First-In-Class Covalent Allosteric Inhibitor of SUMO E1 Activating Enzyme.

Magin, Robert S; Doherty, Laura M; Buhrlage, Sara J

Magin, Robert S; Doherty, Laura M; Buhrlage, Sara J.

Afiliação

Magin RS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
Doherty LM; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA; Department of Systems Biology and Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
Buhrlage SJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA. Electronic address: saraj_buhrlage@dfci.harvard.edu.

Cell Chem Biol ; 26(2): 153-155, 2019 02 21.

Article em En | MEDLINE | ID: mdl-30794786

ABSTRACT

ABSTRACT

SUMOylation is a post-translational modification with important roles in normal physiology and whose dysregulation is associated with human diseases. In this issue of Cell Chemical Biology, Li et al. (2019) describe a covalent, allosteric inhibitor of the SUMO E1 enzyme and demonstrate its anti-tumor activity in preclinical models of colorectal cancer.

Assuntos

Sumoilação; Ubiquitina; Humanos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ubiquitina / Sumoilação Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Cell Chem Biol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google